Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C‐Registry. (30th May 2021)

• Record Type: Journal Article
• Authors: Klinker, Hartwig; Naumann, Uwe; Rössle, Martin; Berg, Thomas; Bondin, Mark; Lohmann, Kristina; Koenig, Bettina; Zeuzem, Stefan; Cornberg, Markus
• Is Part Of: Liver international. Volume 41:Number 7(2021)
• Page Start: 1518
• Page End: 1522
• Publication Date: 2021-05-30
• Subjects: 8 weeks -- cirrhosis -- glecaprevir -- hepatitis C virus -- pibrentasvir; Liver -- Periodicals; Liver -- Diseases -- Periodicals; 616.362
• DOI: 10.1111/liv.14937
• Languages: English
• ISSNs: 1478-3223

Abstract

Abstract: Glecaprevir/pibrentasvir, a pangenotypic, direct‐acting antiviral combination approved for chronic hepatitis C virus treatment, has limited real‐world evidence supporting 8‐week therapy in compensated cirrhosis. We investigated effectiveness and safety of 187 hepatitis C virus‐infected, treatment‐naïve, patients with compensated cirrhosis receiving 8‐week glecaprevir/pibrentasvir therapy in the German Hepatitis C‐Registry between 2 August 2017 and 1 January 2020. Sustained virologic response was 98.4% (127/129) in the per‐protocol analysis (excluding patients lost to follow‐up or who discontinued treatment due to compliance) and was 85.8% (127/148) in patients with data available in an intention‐to‐treat analysis. Nineteen patients were lost to follow‐up; nine genotype 3 patients, nine nongenotype 3 patients and one mixed genotype patient. One patient relapsed, and one died, unrelated to treatment. Adverse events (>5%) were fatigue and headache. Two serious adverse events occurred; no adverse events resulted in drug discontinuation. An 8‐week glecaprevir/pibrentasvir therapy was effective and well‐tolerated in this real‐world analysis.